cetuximab + cisplatin + docetaxel

The combination of cetuximab, cisplatin, and docetaxel (often referred to as TPEx regimen in clinical settings) is used primarily for treating squamous cell carcinoma of the head and neck (SCCHN). This combination therapy has been studied in various clinical trials for both recurrent/metastatic disease and locally advanced disease. ## Mechanism and Clinical Use Cetuximab is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR), interfering with tumor cell growth and spread[4]. Cisplatin and docetaxel are chemotherapy agents that work through different mechanisms to stop tumor cell growth - cisplatin by damaging DNA and docetaxel by disrupting cell division[4][7]. The TPEx regimen typically consists of: - Cetuximab: Initial loading dose of 400 mg/m² followed by weekly doses of 250 mg/m² - Docetaxel: 75 mg/m² administered intravenously - Cisplatin: 75 mg/m² administered intravenously These drugs are usually administered in cycles every 3 weeks for up to three or four cycles, followed by maintenance therapy with cetuximab alone[1][3][6]. ## Clinical Evidence Several clinical studies have evaluated this combination: - The GORTEC study assessed cisplatin, docetaxel, and cetuximab as first-line treatment in 54 patients with recurrent or metastatic SCCHN[1]. - A multicenter cohort study in Argentina evaluated the TPEx regimen as first-line therapy in advanced SCCHN, showing acceptable efficacy and safety profiles[1]. - A phase II trial (ECHO-07) evaluated the cetuximab-TPF combination (ETPF) as induction therapy in patients with locally advanced resectable SCC of the oropharynx[3]. - A multicenter phase II trial in Japan showed a 72.2% overall response rate with a 3-year overall survival of 90.7% when using TPEx followed by cetuximab with concurrent radiotherapy for locally advanced SCCHN[6]. ## Safety Profile The most common adverse events associated with this combination include: - Febrile neutropenia (reported in up to 39% of patients)[6] - Allergic or infusion reactions (reported in up to 11% of patients)[6] Due to these concerns, primary prophylaxis with granulocyte colony stimulating factors (G-CSF) is often required during treatment[3]. ## Current Development Status This combination continues to be studied in various clinical trials, including: - As first-line treatment for recurrent or metastatic head and neck cancer - As induction therapy followed by radiation for locally advanced disease - In palliative treatment settings for SCCHN While showing promising efficacy, the high frequency of febrile neutropenia remains a challenge that requires careful management[6].

Other names

TPEx regimen